Revelation Biosciences, Inc.
NASDAQ: REVBW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Rolke
- Employees
- 8
- Headquarters
- San Diego, United States
- IPO year
- 2022
- Market cap
- $36.7K
- Website
- https://www.revbiosciences.com
Loading REVBW…
Loading profile data…Frequently asked questions about REVBW
What does Revelation Biosciences, Inc. (REVBW) do?
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering immunology-based therapies and diagnostic tools aimed at preventing and treating a range of illnesses. Their flagship therapeutic, REVTx-99, is an intranasal immunomodulator designed to both prevent and treat a broad spectrum of respiratory viral infe...
Where does REVBW trade?
Revelation Biosciences, Inc. (REVBW) trades on the NASDAQ Global Market.
What sector is REVBW in?
Revelation Biosciences, Inc. (REVBW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Revelation Biosciences, Inc.?
James Rolke is the chief executive officer of Revelation Biosciences, Inc. (REVBW).
Where is Revelation Biosciences, Inc. headquartered?
Revelation Biosciences, Inc. is headquartered in United States.
Does REVBW pay a dividend?
Revelation Biosciences, Inc. (REVBW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did REVBW go public?
Revelation Biosciences, Inc. (REVBW) completed its initial public offering in 2022.